Atlas Trials

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Clinical trial NCT01761266 · COMPLETED

Trial details

NCT number
NCT01761266
Sponsor
Eisai Limited
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Hepatocellular Carcinoma (HCC)
Start date
2013-03-01
Primary completion
2016-11-13
Enrollment
954

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.